This paper deals with optimization of a liquid-liquid extraction procedure for simultaneous HPLC analysis of domperidone and pantoprazole in human plasma. Central composite design and Derringer's desirability function were used to optimize the concentration of KOH and the volume of ethyl acetate as the main factors affecting the liquid-liquid extraction procedure. After extraction, the analytes were separated quantitatively on a C18 column with 10 mM pH 7.0 phosphate buffer-methanol-acetonitrile 48.46:20:31.54 (υ/υ) as mobile phase at a flow rate of 1.20 mL min−1 and with UV detection at 285 nm. It was concluded that extraction recovery of both the analytes was affected by KOH concentration and that recovery of pantoprazole was affected by ethyl acetate (extraction solvent) volume. Extraction recovery under optimum extraction conditions was 93.52% for domperidone and 92.72% for pantoprazole. The optimized extraction method was validated. Linearity was established for six levels in the ranges 10–1000 ng mL−1 for pantoprazole and 15–1000 ng mL−1 for domperidone. The lower limit of quantitation (LLOQ) and detection (LOD) were estimated as 9.84 and 5.91 ng mL−1, respectively, for pantoprazole and 14.56 and 8.79 ng mL−1 for domperidone. The optimized method was linear, specific, accurate, and precise; the high recovery (>92%) and low relative standard deviation (<2.5%) enable reliable quantification of these analytes in spiked human plasma.
[1]. A. Fitton L. Wiseman 1995 Drugs 51 460.
[2]. J.A. Barone 1999 Ann. Pharmacother. 33 429.
[3]. R. Huber W. Muller M.C. Banks S.J. Rogers P.C. Norwood E. Doyle 1990 J. Chromatogr. 529 389.
[4]. N.V.S. Ramakrishna K.N. Vishwottam S. Wishu M. Koteshwara 2005 J. Chromatogr. B 822 326.
[5]. M. Tanaka H. Yamazaki 1996 Anal, Chem. 68 1513.
[6]. Q.B. Cass A.L.G. Degani N.M. Cassiano J. Pedrazolli Jr 2001 J. Chromatogr. B 766 153.
[7]. O. Peres C.H. Oliveira A.R.E. Barrientos V.M. Rezende G. de -Nucci 2004 Arzneimittelforschung 54 314.
[8]. I. Heykants R. Hendriks W. Meuldermans M. Michiels H. Scheygrond H. Reyntjens 1981 Eur. J. Drug Metab. Pharmacokinet. 6 61.
[9]. Y.C. Huang J.L. Colaizzi R.H. Bierman R. Woestenborghs J.J. Heykants 1986 J. Clin. Pharmacol. 26 628.
[10]. W. Meuldermans R. Hurkmans E. Swysen J. Hendricks M. Michiels W. Lauwers J. Heykants 1981 Eur. J. Drug Metab. Pharmacokinet. 6 49.
[11]. M. Michiels R. Hendriks J. Heykants 1981 Eur. J. Drug Metab. Pharmacokinet. 6 37.
[12]. K. Yamamoto M. Hagino H. Kotaki T. Iga 1998 J. Chromatogr. B 720 251.
[13]. M. Kobylinska K. Kobylinska 2000 J. Chromatogr. B 744 207.
[14]. A.P. Zavitsanos C. MacDonald E. Bassoob D. Gopaul 1999 J. Chromatogr. B 730 9.
[15]. M.J. Smit F.C.W. Sutherland H.K.L. Hundt K.J. Swart A.F. Hundt J. Els 2002 J. Chromatogr. A 949 65.
[16]. M.J. Sáiz-Abajo J.M. González-Sáiz C. Pizarro 2005 Anal. Chim. Acta 528 63.
[17]. T. Sivakumar R. Manavalan K. Valliappan 2007 Acta Chromatogr. 19 29.
[18]. T. Sivakumar R. Manavalan C. Muralidharan K. Valliappan 2007 J. Sep. Sci. 30 3143.
[19]. T. Sivakumar R. Manavalan C. Muralidharan K. Valliappan 2007 J. Pharm. Biomed. Anal. 43 1842.
[20]. FDA-Center for Drug Evaluation and Research (CDER): Guidance for industry, Bioanalytical method validation, 2001.
[21]. S. Mitra 2003 Sample Preparation Techniques in Analytical Chemistry John Wiley and Sons Hoboken, New Jersey 37–138.
[22]. A. Jadoul V. Préat 1997 Int. J. Pharm. 154 229.
[23]. K. Florey 2002 Analytical Profiles of Drug Substances and Excipients Elsevier Science New York 213–259.
[24]. T. Lundstedt E. Seifert L. Abramo B. Thelin Nyström J. Pettersen R. Bergman 1998 Chemom. Intell. Lab. Syst. 42 3.
[25]. Q. Beg V. Sahai R. Gupta 2003 Process Biochem. 39 203.
[26]. G. Derringer R. Suich 1980 J. Qual. Technol. 12 214.
[27]. P. Wester J. Gottfries K. Johansson F. Klintebäck B. Winblad 1987 J. Chromatogr. 415 261.